MRC - Fighting cancer like an infection
Friday, 30 September 2016 10:03
Professors Irv Weissman and Ravi Majeti at Stanford University and Professor Paresh Vyas at the MRC Molecular Haematology Unit in Oxford, are working on an antibody from the Stanford investigators that enables the immune system to detect and kill cancer cells. They are now testing whether it’s safe and effective for use in people with blood cancer. Find out how they collaborated across the Atlantic to get public funding for a project that has led to a spin out with multiple backers and a promising clinical trial.
Revised DH contract will benefit researchers and patients
Tuesday, 27 September 2016 10:18
The Department of Health (DH) and the Health Research Authority (HRA) have been working together to review the standard DH contract for NIHR funded research. From 4th August 2016 research funded by an NIHR research programme has been able to receive payments for start-up in advance of ethical approval. This enables more rapid, efficient and streamlined set-up of research and quicker translation of research into patient benefit.
This change will enable the appointment of skilled research staff earlier in the project leading to better quality applications for HRA Approval, fewer protocol amendment applications early on in the project, and a quicker and more efficient start up process.
'Library' of nearly 50 de-prioritised pharma compounds opens to researchers
Tuesday, 27 September 2016 10:05
A collection of 47 deprioritised pharmaceutical compounds and up to £5million is being made available to academic researchers through the latest round of the MRC-Industry Asset Sharing Initiative. The collaboration, between the MRC and six global drug companies, is the largest of its kind in the world.
UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease, which may lead to the development of more effective treatments for a range of conditions.
Both clinical (those already tested in humans) and preclinical compounds feature in the extensive collection, which includes molecules developed initially for a wide range of diseases including for cancer, ADHD, narcolepsy and diabetes.
AstraZeneca, GSK, Janssen, Pfizer, Takeda and UCB have each offered up a number of their deprioritised molecules as part of the partnership, which was initially launched in 2014.
Prizes for collaborative regenerative medicine researchers
Tuesday, 27 September 2016 10:00
The UK Regenerative Medicine Platform (UKRMP) has awarded special merit prizes to two postdoctoral researchers who have demonstrated outstanding work on leading creative new approaches to help members of the Platform work together effectively and accelerate discovery.
The UKRMP aims to address the key translational challenges of regenerative medicine – a branch of science that aims to repair or replace damaged and diseased human cells and tissues. It brings together academic expertise, innovation and knowledge with commercial and clinical end-users.
Central to the Platform are five interdisciplinary and complementary research Hubs that collectively provide a national resource to researchers by generating new tools, protocols and resources that can be utilised by other UK research groups in both academia and industry.
Page 8 of 30